Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Evolocumab vs LDL Apheresis Evaluated

Atherosclerosis; 2017 Oct; Kawashiri, et al

In patients with heterozygous familial hypercholesterolemia (HeFH) withdrawing from regular apheresis, treatment with evolocumab significantly reduced low-density lipoprotein cholesterol (LDL-C) when compared with LDL apheresis, a recent study found. 11 patients with HeFH undergoing biweekly LDL apheresis were switched to a biweekly subcutaneous injection of 140 mg of evolocumab. The primary endpoints were percent changes in mean LDL-C and apolipoprotein B (apoB) serum levels. Researchers found:

  • Evolocumab significantly reduced LDL-C by 62.5% compared with LDL apheresis.
  • apoB and serum lipoprotein (a) levels were also significantly reduced.
  • No adverse effects were observed other than a mild reduction in vitamin E serum levels.
  • Biweekly evolocumab injection therapy is less expensive and less time-consuming compared to biweekly LDL apheresis.

Citation:

Kawashiri M, Nohara A, Higashikata T, et al. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis. 2017;265:225-230. doi:10.1016/j.atherosclerosis.2017.09.011.

This Week's Must Reads

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al

Must Reads in Hypercholesterolemia

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al